Wall Street Zen Upgrades Prestige Consumer Healthcare (NYSE:PBH) to Buy

Wall Street Zen upgraded shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a hold rating to a buy rating in a report issued on Saturday morning.

Separately, Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

PBH stock traded down $0.20 during mid-day trading on Friday, hitting $79.98. The company had a trading volume of 243,045 shares, compared to its average volume of 306,011. The company has a market capitalization of $3.95 billion, a price-to-earnings ratio of 18.64, a P/E/G ratio of 2.40 and a beta of 0.43. Prestige Consumer Healthcare has a 12-month low of $64.94 and a 12-month high of $90.04. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $84.17 and a 200 day moving average price of $82.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The business had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same quarter in the previous year, the company earned $1.02 EPS. The business's quarterly revenue was up 7.0% compared to the same quarter last year. On average, research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently added to or reduced their stakes in the company. Cerity Partners LLC grew its holdings in Prestige Consumer Healthcare by 3.7% during the 1st quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock valued at $315,000 after purchasing an additional 132 shares during the last quarter. Franklin Resources Inc. grew its holdings in Prestige Consumer Healthcare by 0.7% during the 4th quarter. Franklin Resources Inc. now owns 21,735 shares of the company's stock valued at $1,697,000 after purchasing an additional 150 shares during the last quarter. KBC Group NV grew its holdings in Prestige Consumer Healthcare by 7.4% during the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after purchasing an additional 151 shares during the last quarter. CIBC Private Wealth Group LLC grew its holdings in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after purchasing an additional 152 shares during the last quarter. Finally, McIlrath & Eck LLC grew its holdings in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.